The Locoregional Recurrence Risk and Failure Pattern for Breast Cancer Patients with 1 to 3 Positive Nodes and Treated with Mastectomy and Contemporary Systemic Therapy
R. Peng,S. Wang,Y. Song,J. Jin,Y. Liu,X. Liu,Z. Yu,Y. Li
DOI: https://doi.org/10.1016/j.ijrobp.2016.06.732
2016-01-01
Abstract:To evaluate risk factors of locoregional recurrence and role of postmastectomy radiation therapy (PMRT) for early stage intermediate risk (T1-2N1M0) breast cancer, and to analyze failure pattern to define the radiation target. A total of 1,348 patients with T1-2 breast cancer and 1 to 3 positive lymph nodes treated with mastectomy without neoadjuvant chemotherapy during 1999-2010 were retrospectively analyzed. 630 (46.7%) patients were T1 and 709 (52.6%) were T2. 667 (49.5%), 417 (30.9%) and 264 (19.6%) patients have 1, 2 and 3 axillary positive lymph node. The molecular subtypes included luminal A (67.5%), luminal B (10.9%), HER2 positive (5.5%) and triple negative (13.6%). 235 (17.4%) patients received PMRT, 1249 (92.7%) received adjuvant chemotherapy, 958 (73.5%) received adjuvant hormonal therapy, and 39 (2.9%) received adjuvant trastuzumab. Overall survival (OS) and locoregional recurrence rate (LRR) rates were calculated by Kaplan-Meier analysis and compared by log-rank test. Cox logistic regression analysis was performed. The median survival time was 79 months. Overall, the 5-year and 10-year LRFS were 97.0% and 94.8%, and cumulative LRFS were 95.7% and 91.6%, respectively. The 5-year LRFS were not statistically different between patients with or without PMRT (95.9% VS 94.5%, P = 0.338). However, multivariate analysis showed that without PMRT was a significant predictor of LRR (P = 0.037, HR = 2.519, 95% CI 1.058 - 6.000). On Multivariate analysis in patients who did not receive PMRT, significant factors associated with an increased risk of LRR were T2 stage (P = 0.014, HR = 2.146, 95% CI 1.170-3.936), PR negative (P = 0.017, HR = 2.651, 95% CI 1.189-5.911) and percentage of positive lymph node (PLN) >10% (P = 0.026, HR = 0.532, 95% CI 0.305-0.928). Molecular subtype were not prognostic factors for LRR, and only Luminal A showed a trend (P = 0.080) for lower LRR. In patients without PMRT who had 3 risk factors, the 5-year and 10-year LRR was both 15.7%. Supraclavicular region and chest wall were the primary failure pattern of recurrence, with similar risk of 48.1% and 50.0%. In patients with T1-2N1 breast cancer with mastectomy, LRR rates are very low with contemporary systemic therapy. Risk factors of LRR included T2 stage, PR negative and PLN >10%. PMRT should be considered for patients with all 3 risk factors, and supraclavicular region and chest wall should be irradiated. The value of molecular subtype for LRR is not clear, further research on this subject is justified.